Amgen Ventures is Amgen’s corporate venture-capital function, established November11,2004 to support emerging biotechnology companies and human therapeutics. Its legal investment entity Amgen Ventures LLC is expressly identified in issuer SEC disclosures as a wholly owned subsidiary of Amgen Inc.; Amgen’s own2025 participating-company list independently names that LLC at OneAmgenCenterDrive,ThousandOaks. The retained institutional buyer profile represents the branded venture function and documented LLC, rather than automatically attributing every venture investment directly to the parent. Amgen Ventures invests in therapeutics, drug discovery, new biological modalities, healthcare technology and digital analytics, including neuroscience, neurodegeneration and AI-enabled discovery. Its current own business-development directory identifies Gladys Nunez as Executive Director,Ventures and Joshua Crapser and Jacob Tutor as Managers within Amgen Ventures. Rachna Khosla’s SeniorVicePresident,BusinessDevelopment role expressly oversees the venture function and is qualified as corporate oversight. Historical Janis Naeve and Samantha Palmer leadership references are not substituted for the live current roster. The current website reports over1B in equity investment and over70 investments: cumulative deployment, not a newly closed LP fund. The original2004 initial100M corporate commitment and a later brochure’s625M sponsor commitment/over400M deployment likewise describe corporate investment capacity/history, not verified outside-LP closes. GoldenTicket laboratory support, commercial partnerships and equity investment are distinguished. Exact current separate LP fund vehicles or actual LP closings are not established by reviewed primary evidence. All preexisting portfolio records, roles and personal attributions are preserved.